Skip to main content

Advertisement

Fig. 2 | Virology Journal

Fig. 2

From: Molecular and serological characterization of hepatitis B vaccine breakthrough infections in serial samples from two plasma donors

Fig. 2

Serological and molecular profiles for panel 11,000. Panel 11,000 was tested with ARCHITECT HBsAg Qual II, a prototype ARCHITECT HBsAg assay, a research assay for preS2 antigen, ARCHITECT Anti-HBs, Lumipulse HBcrAg, and Abbott RealTime HBV. An S/CO value ≥ 1.0 was considered reactive for the HBsAg and preS2 assays. The limit of quantitation of the HBcrAg assay is 3 log U/ml; results for samples prior to day 21 were below the measuring range of the assay and were omitted from the figure. Anti-HBs levels ≥ 10 mIU/ml are considered protective

Back to article page